Published Studies Related to Ismotic (Isosorbide)
Randomized controlled trial of the efficacy of isosorbide-SR addition to current treatment in medical expulsive therapy for ureteral calculi. [2011.10]
It has been suggested that nitrates are potent smooth muscle relaxants that may reduce pain and facilitate ureteral stone passage; therefore it may be an option for medical expulsive therapy in ureteral stones. In a prospective randomized controlled clinical trial, we evaluated the efficacy of medical expulsive therapy with isosorbide-SR 40 mg in patients with ureteral stones (</=10 mm)...
Intravaginal administration of isosorbide mononitrate and misoprostol for cervical ripening and induction of labour: a randomized controlled trial. [2011.07]
BACKGROUND: Labor induction in the presence of unfavorable cervix is a common indication for the use of prostaglandins. However, in the last years, there has been a considerable interest in the use of nitrous oxide donors for cervical ripening and labor induction. OBJECTIVE: To evaluate the efficacy and safety of intravaginal administration of NOD isosorbide mononitrate (IMN) plus misoprostol versus misoprostol alone for cervical ripening and induction of labor. SETTING: Department of Obstetrics and Gynecology, Woman's Health Center, Assiut University... CONCLUSIONS: Using a combination of IMN and misoprostol is more efficient than misoprostol alone in terms of fast cervical ripening and shortening of induction-labour interval.
Comparison of isosorbide mononitrate and misoprostol for cervical ripening in termination of pregnancy between 8 and 12 weeks: a randomized controlled trial. [2011.06]
AIM: The present study was undertaken to compare the efficacy of isosorbide mononitrate (IMN) and misoprostol for cervical ripening in termination of pregnancy between 8 and 12 weeks... CONCLUSION: The results show that IMN has a definite role and better safety profile than misoprostol in first trimester cervical ripening, although misoprostol is more effective and causes less blood loss.
[Comparison of isosorbide dinitrate and dinoprostone for induction of labor in term pregnancy]. [2011.05]
CONCLUSIONS: the isosorbide dinitrate is associated with lower duration of labor compared with dinoprostone. There was no difference in the maternal-fetal outcome by using whatever drug.
Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate. [2011.03]
BACKGROUND: Hypertension and left ventricular hypertrophy (LVH) are independent predictors of morbidity and mortality in maintenance hemodialysis (MHD) patients. The level of serum asymmetric dimethylarginine (ADMA) is increased in MHD patients, which is a kind of uremic toxin. It can competitively inhibit nitric oxide production from L-arginine, which can increase vascular resistance, then lead to endothelium dysfunction, hypertension, LVH and decrease of ejection fraction. A sustained-release preparation of isosorbide mononitrate can lead to vasodilatation by releasing nitrogen monoxide. But it remains unclear whether oral isosorbide mononitrate in MHD patients can control blood pressure (BP) and reverse LVH. The aim of the present study was to evaluate the safety and efficacy of oral sustained-release isosorbide mononitrate on hypertension and LVH in MHD patients... CONCLUSIONS: Sustained-release isosorbide mononitrate, which is safe and well tolerated, can effectively control BP, decrease the category and quantity of hypotensive drugs, improve left ventricular hypertrophy and reduce the incidence of acute left heart failure in MHD patients.
Clinical Trials Related to Ismotic (Isosorbide)
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma [Active, not recruiting]
This is a phase II clinical trial in patients who have not received systemic treatment for
follicular non-Hodgkin's lymphoma. The study combines rituximab, an approved drug for this
disease, with AT-101, an experimental drug. The hypothesis is that by adding AT-101 to the
rituximab regimen, improvement to patients' response to the treatment will be observed verses
A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis [Recruiting]
This study investigates the effective power of angina pectoris after Quick-Acting Heart
Reliever and isosorbide dinitrate interventing respectively the patients with moderate
coronary stenosis for six months. At the same time, the studying will assess the plaque,
myocardial blood-supplying,quality of life and observe the end point of the heart (including
the myocardial revascularization, death and myocardial infarction). The purpose is to study
the function of the blood-quickening stasis-transforming formula Quick-Acting Heart Reliever
for moderate coronary stenosis lesions.
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer [Active, not recruiting]
This is an open label, multicenter Phase I/II study to evaluate the safety and efficacy of
AT-101 in combination with topotecan in relapsed/refractory small cell lung cancer
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer [Recruiting]
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of
AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate
cancer that are either chemotherapy naive or have received and progressed on a docetaxel
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer [Recruiting]
This is a double- blind, multicenter, randomized Phase II study to evaluate the efficacy and
safety of AT-101 in combination with docetaxel in relapsed/refractory non-small cell lung